Literature DB >> 20648057

Potential role of TCF7L2 gene variants on cardiac sympathetic/parasympathetic activity.

Virginia Boccardi1, Immacolata Ambrosino, Michela Papa, Daniela Fiore, Maria Rosaria Rizzo, Giuseppe Paolisso, Michelangela Barbieri.   

Abstract

Variants in transcription factor 7-like 2 (266096218TCF7L2266096218USuser266096218Gene names have been italicized per house style. Please check and confirm whether there are other instances that need to be italicized or instances where italics have been inappropriately applied.) gene have been found strongly associated with an increased risk of type 2 diabetes, as well as with an impairment of glucagon-like peptide-1 (GLP-1) signalling chain. In rats, stimulation of central GLP-1 receptors increases heart rate and activates autonomic regulatory neurons. We aimed to evaluate the potential role of TCF7L2 gene polymorphisms on sympathovagal response in relation to changes in plasma insulin and/or GLP-1 concentration after glucose ingestion. Genotyping was performed for rs12255372 and rs7903146 TCF7L2 gene variants in 250 non-related healthy volunteers (mean age 27±3 years). Consistent with previous reports, both single-nucleotide polymorphisms were in strong linkage disequilibrium (D'=0.87, r(2)=0.76). A subset of 167 patients underwent an oral glucose tolerance test while a continuous recording of heart rate variability was performed. At baseline, no differences in fasting plasma insulin, in GLP-1 levels and in LF/HF (low frequency/high frequency) ratio between the three genotypes were found. Along with glucose ingestion TT subjects had lower INS(AUC) (insulin area under curve), as well as higher LF/HF(AUC) (LF/HF area under curve) values. No difference in GLP-1(AUC) (GLP-1 area under curve) between TCF7L2 gene variants was found. A multivariate analysis including multiple covariates showed that only INS(AUC,) GLP-1(AUC) and TCF7L2 gene variants were independently associated with LF/HF(AUC). In conclusion, TT genotype of rs12255372 and rs7903146 TCF7L2 gene variants is associated with lower insulin secretion and higher cardiosympathetic activity. Moreover, such effect is independent of GLP-1 and insulin plasma concentrations suggesting a potential role of such gene variants in increasing cardiovascular risk through enhanced sympathetic nervous system activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20648057      PMCID: PMC3002850          DOI: 10.1038/ejhg.2010.117

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  35 in total

1.  TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta.

Authors:  Fenghua Yi; Patricia L Brubaker; Tianru Jin
Journal:  J Biol Chem       Date:  2004-11-02       Impact factor: 5.157

2.  Glucose ingestion affects cardiac ANS in healthy subjects with different amounts of body fat.

Authors:  G Paolisso; D Manzella; N Ferrara; A Gambardella; P Abete; M R Tagliamonte; D De Lucia; G Furgi; C Picone; S Gentile; F Rengo; M Varricchio
Journal:  Am J Physiol       Date:  1997-09

Review 3.  Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.

Authors:  H C Fehmann; R Göke; B Göke
Journal:  Endocr Rev       Date:  1995-06       Impact factor: 19.871

4.  Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

Authors: 
Journal:  Eur Heart J       Date:  1996-03       Impact factor: 29.983

5.  Effects of different insulin infusion rates on heart rate variability in lean and obese subjects.

Authors:  G Paolisso; D Manzella; M R Tagliamonte; M R Rizzo; A Gambardella; M Varricchio
Journal:  Metabolism       Date:  1999-06       Impact factor: 8.694

Review 6.  Heart rate variability: measurement and clinical utility.

Authors:  Robert E Kleiger; Phyllis K Stein; J Thomas Bigger
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-01       Impact factor: 1.468

7.  Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

Authors:  Thomas Nyström; Mark K Gutniak; Qimin Zhang; Fan Zhang; Jens Juul Holst; Bo Ahrén; Ake Sjöholm
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-09-07       Impact factor: 4.310

8.  Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system.

Authors:  I Merchenthaler; M Lane; P Shughrue
Journal:  J Comp Neurol       Date:  1999-01-11       Impact factor: 3.215

9.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

10.  Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences.

Authors:  Y Wei; S Mojsov
Journal:  FEBS Lett       Date:  1995-01-30       Impact factor: 4.124

View more
  4 in total

Review 1.  Association between genetics of diabetes, coronary artery disease, and macrovascular complications: exploring a common ground hypothesis.

Authors:  André G Sousa; Lívia Selvatici; José E Krieger; Alexandre C Pereira
Journal:  Rev Diabet Stud       Date:  2011-08-10

2.  rs7903146 polymorphism at transcription factor 7 like 2 gene is associated with total cholesterol and lipoprotein profile in HIV/hepatitis C virus-coinfected patients.

Authors:  Daniel Pineda-Tenor; Juan Berenguer; María A Jiménez-Sousa; Ana Carrero; Mónica García-Álvarez; Teresa Aldámiz-Echevarria; Pilar García-Broncano; Cristina Diez; María Guzmán-Fulgencio; Amanda Fernández-Rodríguez; Salvador Resino
Journal:  AIDS Res Hum Retroviruses       Date:  2014-10-29       Impact factor: 2.205

Review 3.  The broad pathogenetic role of TCF7L2 in human diseases beyond type 2 diabetes.

Authors:  Laura Del Bosque-Plata; Eduardo Pavel Hernández-Cortés; Claudia Gragnoli
Journal:  J Cell Physiol       Date:  2021-10-06       Impact factor: 6.513

4.  Targeted deletion of Tcf7l2 in adipocytes promotes adipocyte hypertrophy and impaired glucose metabolism.

Authors:  Gisela Geoghegan; Judith Simcox; Marcus M Seldin; Timothy J Parnell; Chris Stubben; Steven Just; Lori Begaye; Aldons J Lusis; Claudio J Villanueva
Journal:  Mol Metab       Date:  2019-03-14       Impact factor: 7.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.